UA 026
Alternative Names: UA-026Latest Information Update: 03 Jul 2025
At a glance
- Originator Usynova Pharmaceuticals
- Class Antipsoriatics; Small molecules
- Mechanism of Action Interleukin 17 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Plaque psoriasis
Most Recent Events
- 08 May 2025 Phase-I clinical trials in Plaque psoriasis in China (PO) (NCT07038720)